Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to ...

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support ...

Kazo District has been selected among the first districts in Uganda to pilot a new long-acting HIV prevention injection as the country steps up efforts to reduce new infections.The initiative, led by ...

Lenacapavir is a long-acting injectable Pre-Exposure Prophylaxis (PrEP) option administered once every six months ...

Amid ongoing efforts to combat HIV, South Africa initiates the BRILLIANT 011 trial, staking a claim in the search for an ...

The lack of funding has left some 15,000 users of NGO programs scrambling for care in a public system that many fear to enter ...

Trump administration officials are putting forward new data that shows U.S. federal anti-HIV/AIDS funding has continued to curb the worldwide epidemic despite accusations from outside public health ...

Despite a new supply commitment from Gilead Sciences, Doctors Without Borders/Médecins Sans Frontières (MSF) is poking holes ...

By Julie Steenhuysen CHICAGO, April 17 (Reuters) - The U.S. State Department on Friday said it had supported HIV treatment ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug ...

In Malawi, a year after the U.S. Agency for International Development (USAID) was shut down and funding for the President’s ...